Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer

Acta Oncologica

Volumn 55, Issue 7, 2016, Pages 807-813

  Lilleby, Wolfgang ^a   Stensvold, Andreas ^b   Dahl, Alv A ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Østfold Hospital Trust   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; GOSERELIN; ANTIANDROGEN; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER FATIGUE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; STANDARD; ADVERSE EFFECTS; CHEMICALLY INDUCED; CLINICAL TRIAL; FATIGUE; INTENSITY MODULATED RADIATION THERAPY; LONGITUDINAL STUDY; LYMPH NODE; MIDDLE AGED; ORGANS AT RISK; PELVIS; PROCEDURES; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; QUESTIONNAIRE; RADIATION RESPONSE;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; CROSS-SECTIONAL STUDIES; DEPRESSION; FATIGUE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; LYMPH NODES; MALE; MIDDLE AGED; ORGANS AT RISK; PELVIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY, INTENSITY-MODULATED; SURVEYS AND QUESTIONNAIRES;

EID: 84975109081     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2015.1127417     Document Type: Article

References (30)

1. L.K.Morikawa, M.I.I.I.Roach Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int. J Radiat Oncol Biol Phys 2011;80:6–16.
2. M.Pinkawa, M.D.Piroth, R.Holy, V.Djukic, J.Klotz, B.Krenkel,. Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. Strahlenther Onkol 2011;187:479–84.
3. M.J.Zelefsky, E.J.Levin, M.Hunt, Y.Yamada, A.M.Shippy, A.Jackson,. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124–9.
4. W.Lilleby, A.Stensvold, A.A.Dahl Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up. Acta Oncol 2014;53:1380–9.
5. M.J.Zelefsky, Y.Yamada, Z.Fuks, Z.Zhang, M.Hunt, O.Cahlon,. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008;71:1028–33.
6. I.Lips, H.Dehnad, A.B.Kruger, M.J.van, H.U.van der, J.Battermann Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys 2007;69:656–61.
7. V.Marchand, S.Bourdin, C.Charbonnel, E.Rio, C.Munos, L.Campion No impairment of quality of life 18 months after high-dose intensity-modulated radiotherapy for localized prostate cancer: a prospective study. Int J Radiat Oncol Biol Phys 2010;77:1053–9.
8. A.E.Kyrdalen, A.A.Dahl, E.Hernes, E.Hem, S.D.Fossa Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs. Prostate 2010;70:1480–9.
9. A.E.Kyrdalen, A.A.Dahl, E.Hernes, M.Cvancarova, S.D.Fossa Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy. Prostate Cancer Prostatic Dis 2010;13:144–50.
10. C.Wittekind, C.C.Compton, F.L.Greene, L.H.Sobin TNM residual tumor classification revisited. Cancer 2002;94:2511–6.
11. M.I.I.I.Roach, V.Weinberg, M.Nash, H.M.Sandler, P.W.Mclaughlin, M.W.Kattan Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials. J Urol 2006;176:S16–20.
12. A.V.D'amico, J.Moul, P.R.Carroll, L.Sun, D.Lubeck, M.H.Chen Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003;21:2163–72.
13. A.Berg, W.Lilleby, O.S.Bruland, S.D.Fossa 10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy. Int J Radiat Oncol Biol Phys 2007;69:1074–83.
14. W.Lilleby, A.Stensvold, A.A.Dahl Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: A study of adverse effects and their relation to quality of life. Prostate 2013;73:1038–47.
15. J.H.Loge, O.Ekeberg, S.Kaasa Fatigue in the general Norwegian population: normative data and associations. J Psychosom Res 1998;45:53–65.
16. M.S.Litwin, R.D.Hays, A.Fink, P.A.Ganz, B.Leake, R.H.Brook The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998;36:1002–12.
17. I.Bjelland, A.A.Dahl, T.T.Haug, D.Neckelmann The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002;52:69–77.
18. T.Chalder, G.Berelowitz, T.Pawlikowska, L.Watts, S.Wessely, D.Wright Development of a fatigue scale. J Psychosom Res 1993;37:147–53.
19. B.Gandek, J.E.Ware, N.K.Aaronson, G.Apolone, J.B.Bjorner, J.E.Brazier Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998;51:1171–8.
20. M.S.Litwin, R.D.Hays, A.Fink, P.A.Ganz, B.Leake, G.E.Leach,. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995;273:129–35.
21. M.Bolla, T.M.de Reijke, T.G.Van, A.C.Van den Bergh, J.Oddens, P.M.Poortmans,. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516–27.
22. J.W.Denham, D.Joseph, D.S.Lamb, N.A.Spry, G.Duchesne, J.Matthews,. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol 2014;15:1076–89.
23. P.Fransson, J.A.Lund, J.E.Damber, O.Klepp, F.Wiklund, S.Fossa,. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol 2009;10:370–80.
24. H.Geinitz, R.Thamm, C.Scholz, C.Heinrich, N.Prause, S.Kerndl,. Longitudinal analysis of quality of life in patients receiving conformal radiation therapy for prostate cancer. Strahlenther Onkol 2010;186:46–52.
25. W.F.Pirl, J.A.Greer, M.Goode, M.R.Smith Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psychooncology 2008;17:148–53.
26. M.G.Sanda, R.L.Dunn, J.Michalski, H.M.Sandler, L.Northouse, L.Hembroff,. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–61.
27. I.M.Lips, H.Dehnad, C.H.van Gils, A.E.Boeken Kruger, U.A.van der Heide, M.van Vaupel High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients. Radiat Oncol 2008;3:3–15.
28. P.Warde, M.Mason, K.Ding, P.Kirkbride, M.Brundage, R.Cowan,. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011;378:2104–11.
29. A.Widmark, O.Klepp, A.Solberg, J.E.Damber, A.Angelsen, P.Fransson,. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301–8.
30. J.W.Denham, A.Steigler, D.Joseph, D.S.Lamb, N.A.Spry, G.Duchesne,. Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial. Radiother Oncol 2015;115:301–7.